Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$34.17
$0.91(2.74%)
At close: 4:00 PM EDT
$34.17
$0.91(2.74%)
Day’s Range― - ―
52-Week Range$20.65 - $36.93
Previous CloseN/A
Volume255.71K
Average Volume (3M)452.35K
Market Cap
$2.55B
Enterprise Value$1.99K
Total Cash (Recent Filing)$246.96M
Total Debt (Recent Filing)$738.89K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 18, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,863,686
10 Day Avg. Volume276,942
30 Day Avg. Volume452,347
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$48.78Price Target Upside42.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline ProgressAdvancing deucrictibant into pivotal Phase 3 readouts and an imminent U.S. NDA is a structural step toward commercialization. Success would transform Pharvaris from pre-revenue developer into a product-based company, enabling durable revenue streams and de-risking long-term funding dependency.
Extended Cash RunwayA funded runway into 2028 materially reduces near-term financing pressure, allowing completion of late-stage trials, regulatory filings, and initial commercialization investments. This gives management time to execute clinical milestones and pursue partnerships without immediate cash crunch risk.
Low Financial LeverageMinimal debt exposure preserves financial flexibility and limits covenant and interest burdens. For a pre-commercial biotech, low leverage reduces insolvency risk if timelines slip and allows management to prioritize R&D and strategic transactions over servicing debt.
Bears Say
Pre-revenue ProfileOperating without product revenue leaves the company dependent on capital markets and partnerships; until approval and launch, there is no durable internal cash generation. This structural absence of revenue increases exposure to trial setbacks and market funding conditions.
Sustained High Cash BurnConsistent, rising cash burn depletes equity and requires recurrent capital raises or expense curtailment. Over multiple quarters this increases funding risk and can force trade-offs between program advancement, commercialization readiness, and balance-sheet preservation.
Reliance On Equity FinancingFrequent equity raises provide needed capital but dilute shareholders and signal reliance on public markets. Structural dependence on equity issuance creates execution risk if market conditions shift, potentially constraining long-term planning and increasing cost of capital.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $20.65 and its highest was $36.93 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $2.55B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on Aug 12, 2026. The company reported -$0.807 earnings per share for the quarter, missing the consensus estimate of -$0.754 by -$0.053.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate is -0.8.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 69,863,686 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of -$0.807 in its last earnings report, missing expectations of -$0.754. Following the earnings report the stock price went up 5.927%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.78 (42.75% Upside)
$48.78 (42.75% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.57%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Stock 12 Month Forecast
Average Price Target
$48.78
▲(42.75% Upside)
Technical Analysis
Ownership Overview
2.71% Insiders
7.58% Mutual Funds
2.18% Other Institutional Investors
86.34% Public Companies and
Individual Investors